Disease characteristics, treatment, and outcomes in Chinese chronic lymphocytic leukemia patients following BTK inhibitor discontinuation: a multicenter real-world study

Utilization of novel Bruton tyrosine kinase inhibitors (BTKi) has become common for treating CLL/SLL patients, yet limited evidence exists on the clinical characteristics and outcomes following BTKi therapy discontinuation in China. This multicenter retrospective study analyzed 37 CLL/SLL patients i...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yuting Yan, Wei Wang, Xiaojing Yan, Hong Xu, Danyang Wu, Tingyu Wang, Wei Liu, Wenyang Huang, Gang An, Dehui Zou, Jiahuang Lin, Yaqun Fu, Lugui Qiu, Shuhua Yi
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-06-01
Col·lecció:	Frontiers in Medicine
Matèries:	Bruton tyrosine kinase inhibitor chronic lymphocytic leukemia clinical outcome discontinuation small lymphocytic lymphoma
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1739102/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!